251 related articles for article (PubMed ID: 25986733)
1. Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Carrieri PB; Carbone F; Perna F; Bruzzese D; La Rocca C; Galgani M; Montella S; Petracca M; Florio C; Maniscalco GT; Spitaleri DL; Iuliano G; Tedeschi G; Della Corte M; Bonavita S; Matarese G
Metabolism; 2015 Sep; 64(9):1112-21. PubMed ID: 25986733
[TBL] [Abstract][Full Text] [Related]
2. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
3. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms.
Duszczyszyn DA; Beck JD; Antel J; Bar-Or A; Lapierre Y; Gadag V; Haegert DG
Clin Exp Immunol; 2006 Feb; 143(2):305-13. PubMed ID: 16412055
[TBL] [Abstract][Full Text] [Related]
4. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
Front Immunol; 2018; 9():1097. PubMed ID: 29896193
[TBL] [Abstract][Full Text] [Related]
5. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Festoff BW; Li C; Woodhams B; Lynch S
J Neurol Sci; 2012 Dec; 323(1-2):61-5. PubMed ID: 22967748
[TBL] [Abstract][Full Text] [Related]
6. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J
J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847
[TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner J; Koczi W; Harrer A; Oppermann K; Obregon-Castrillo E; Pilz G; Wipfler P; Afazel S; Haschke-Becher E; Trinka E; Kraus J
Clin Exp Immunol; 2013 Sep; 173(3):381-9. PubMed ID: 23611040
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis.
Weder C; Baltariu GM; Wyler KA; Gober HJ; Lienert C; Schluep M; Radü EW; De Libero G; Kappos L; Duda PW
Eur J Neurol; 2005 Nov; 12(11):869-78. PubMed ID: 16241976
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Sellebjerg F; Hesse D; Limborg S; Lund H; Søndergaard HB; Krakauer M; Sørensen PS
Mult Scler; 2013 Feb; 19(2):179-87. PubMed ID: 22653658
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
[TBL] [Abstract][Full Text] [Related]
11. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate.
Chiarini M; Sottini A; Ghidini C; Zanotti C; Serana F; Rottoli M; Zaffaroni M; Bergamaschi R; Cordioli C; Capra R; Imberti L
Mult Scler; 2010 Feb; 16(2):218-27. PubMed ID: 20007428
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.
Weber MS; Starck M; Wagenpfeil S; Meinl E; Hohlfeld R; Farina C
Brain; 2004 Jun; 127(Pt 6):1370-8. PubMed ID: 15090474
[TBL] [Abstract][Full Text] [Related]
14. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.
Khan O; Shen Y; Caon C; Bao F; Ching W; Reznar M; Buccheister A; Hu J; Latif Z; Tselis A; Lisak R
Mult Scler; 2005 Dec; 11(6):646-51. PubMed ID: 16320723
[TBL] [Abstract][Full Text] [Related]
15. The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis.
Blauth K; Zhang X; Chopra M; Rogan S; Markovic-Plese S
Clin Immunol; 2015 Apr; 157(2):121-32. PubMed ID: 25596452
[TBL] [Abstract][Full Text] [Related]
16. Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis.
Mikulkova Z; Praksova P; Stourac P; Bednarik J; Michalek J
J Neurol Sci; 2011 Jan; 300(1-2):135-41. PubMed ID: 20884014
[TBL] [Abstract][Full Text] [Related]
17. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.
Frisullo G; Iorio R; Plantone D; Marti A; Nociti V; Patanella AK; Batocchi AP
Mult Scler; 2011 May; 17(5):556-66. PubMed ID: 21177324
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.
Bomprezzi R; Schaefer R; Reese V; Misra A; Vollmer TL; Kala M
Scand J Immunol; 2011 Sep; 74(3):219-226. PubMed ID: 21615449
[TBL] [Abstract][Full Text] [Related]
19. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
20. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate.
Duda PW; Krieger JI; Schmied MC; Balentine C; Hafler DA
J Immunol; 2000 Dec; 165(12):7300-7. PubMed ID: 11120865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]